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In Response:
We thank Guo et al. for their com-
ment on our article entitled “A Meta-
Analysis of Randomized Controlled Trials
Comparing Irinotecan/Platinum with Eto-
poside/Platinum in Patients with Previ-
ously Untreated Extensive-Stage Small
Cell Lung Cancer.”1 The meta-analysis
was completely accepted for publication
in February 2010, and the new clinical
trial reported by Zatloukal et al.2 was
published online in March 2010; there-
fore, we were unable to add the new trial
to the meta-analysis. Both trials given
carboplatin or cisplatin were included
into the meta-analysis. We also per-
formed sensitivity analysis, after the
trial using carboplatin treatment was ex-
cluded, to identify whether there was
bias caused by different platinum. We
integrated two forest plots into one fig-
ure when the overall analysis and sensi-
tivity analysis were conducted. So, in
this figure, the subgroup of carboplatin
that included only one trial should be
considered as a removed trial by the
sensitivity analysis. This management
did not affect the results of overall anal-
ysis and sensitivity analysis.
Although there is some difference
in the odds ratio (OR) and relative risk
(RR), both OR and RR are effective
measures for dichotomous outcomes in
meta-analysis. The risk ratio (RR) is the
ratio of the risk of an event in the two
groups, whereas the OR is the ratio of
the odds of an event. For both measures,
a value of one indicates that the esti-
mated effects are the same for both treat-
ments, but the interpretation of an OR is
more complicated than for a RR (see
page 75 in Cochrane Reviewers’ Hand-
book 4.2.3). Our results calculated by
OR were also confirmed by RR.
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